Skip to main content

Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials

The AAPS Journal volume 7, pages E143–E148 (2005)Cite this article

Abstract

Ajulemic acid (CT-3, IP-751,1’,1’-dimethylheptyl-Δ8 acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Burstein S. Therapeutic Potential of Ajulemic Acid (CT-3): In: Grontenhermen F, Russo E, eds.Cannabis and Cannabinoids. Binghamton, NY: Haworth Press Inc; 2002;381–388.

    Google Scholar 

  2. Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.Curr Pharm Des. 2000;6:1339–1345.

    PubMed  Article  CAS  Google Scholar 

  3. Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.Pharmacol Ther. 1999;82:87–96.

    PubMed  Article  CAS  Google Scholar 

  4. Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a “high”.Life Sci. 2004;75:1513–1522.

    PubMed  Article  CAS  Google Scholar 

  5. Burstein S, Hunter SA, Latham V, Renzulli L. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.Experientia. 1987;43:402–403.

    PubMed  Article  CAS  Google Scholar 

  6. Burstein S, Shoupe TS. Metabolic pathways for the transformation of delta 1-tetrahydrocannabinol in mouse hepatic microsomes.Drug Metab Dispos. 1981;9:94–96.

    PubMed  CAS  Google Scholar 

  7. Burstein S, Rosenfeld J, Wittstruck T. Isolation and characterization of two major urinary metabolites of 1-tetrahydrocannabinol.Science. 1972;176:422–423.

    PubMed  Article  CAS  Google Scholar 

  8. Burstein SH, Kupfer D. Hydroxylation of trans-1-tetrahydrocannabinol by a hepatic microsomal monooxygenase.Chem Biol Interact. 1971;3:316.

    PubMed  Article  CAS  Google Scholar 

  9. Burstein SH, Menezes F, Williamson E, Mechoulam R. Metabolism of delta 1(6)-tetrahydro-cannabinol, an active marihuana constituent.Nature, 1970;225:87–88.

    PubMed  Article  CAS  Google Scholar 

  10. Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, eds.Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publishers; 1985;287–310.

    Google Scholar 

  11. Burstein S, Hunter SA, Latham V, Renzulli L. Prostaglandins and cannabis-XVI. Antagonism of delta 1-tetrahydrocannabinol action by its metabolites.Biochem Pharmacol. 1986;35:2553–2558.

    PubMed  Article  CAS  Google Scholar 

  12. Burstein SH, Hull K, Hunter SA, Latham V. Cannabinoids and pain responses: a possible role for prostaglandins.FASEB J. 1988;2:3022–3026.

    PubMed  CAS  Google Scholar 

  13. Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V. Antagonism to the actions of platelet activating factor by a non-psychoactive cannabinoid.J Pharmacol Exp Ther. 1989;251:531–535.

    PubMed  CAS  Google Scholar 

  14. Doyle SA, Burstein SH, Dewey WL, Welch SP. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid.Agents Actions. 1990;31:157–163.

    PubMed  Article  CAS  Google Scholar 

  15. Burstein SH, Audette CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.J Med Chem. 1992;35: 3135–3141.

    PubMed  Article  CAS  Google Scholar 

  16. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.JAMA. 2003;290: 1757–1762.

    PubMed  Article  CAS  Google Scholar 

  17. Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.J Med Chem. 1997;40:3228–3233.

    PubMed  Article  CAS  Google Scholar 

  18. Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.J Pharmacol Exp Ther. 1993;265:218–226.

    PubMed  CAS  Google Scholar 

  19. Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.Biochem Pharmacol. 2001;62:755–763.

    PubMed  Article  CAS  Google Scholar 

  20. Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis.Life Sci. 1997;60:1563–1573.

    PubMed  Article  CAS  Google Scholar 

  21. Stebulis JA, Burstein SH, Torres R, et al. Ajulemic Acid, an antiinflammatory nonpsychoactive cannabinoid acid, modulates activation of human synovial cells. Paper presented at: 2004 Symposium on the Cannabinoids. June 20, 2004; Paestum, Italy.

  22. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11-oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure.Arthritis Rheum. 1998;41:163–170.

    PubMed  Article  CAS  Google Scholar 

  23. Dajani EZ, Larsen KR, Taylor J, et al. 1′,1′-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.J Pharmacol Exp Ther. 1999;291:31–38.

    PubMed  CAS  Google Scholar 

  24. Burstein SH, Friderichs E, Kogel B, Schneider J, Selve N. Analgesic effects of 1′,1′ dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice.Life Sci. 1998;63:161–168.

    PubMed  Article  CAS  Google Scholar 

  25. Bidinger B, Torres R, Rossetti RG, et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.Clin Immunol. 2003;108:95–102.

    PubMed  Article  CAS  Google Scholar 

  26. Liu J, Li, H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.Mol Pharmacol. 2003;63:983–992.

    PubMed  Article  CAS  Google Scholar 

  27. Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1 beta production by ajulemic acid, a nonpsychoactive cannabinoid.Biochem Pharmacol. 2003;65:649–655.

    PubMed  Article  CAS  Google Scholar 

  28. Walker JM, Owen K, Petros P, Huang SM. Antiallodynic and analgesic actions of ajulemic acid reversed by a cannabinoid antagonist. Paper presented at: Society of Neuroscientists; November 9, 2000; New Orleans, LA.

  29. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.Arthritis Rheum. 2004;50:985–998.

    PubMed  Article  CAS  Google Scholar 

  30. Burstein SH, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al.Arthritis Rheum. 2004;50:4078–4080.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, 01605, Worcester, MA

    Summer Burstein

Authors
  1. Summer Burstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Summer Burstein.

Additional information

Published: June 29, 2005

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Burstein, S. Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 7, E143–E148 (2005). https://doi.org/10.1208/aapsj070115

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1208/aapsj070115

Keywords

  • ajulemic acid
  • analgesia
  • anti-inflammatory
  • cannabinoid
  • IP-751